The A2M Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the A2M gene is disrupted in the human SK-HEP-1 hepatic adenocarcinoma cell line. This heterogeneous pool contains diverse loss-of-function mutations, enabling investigation of alpha-2-macroglobulin (A2M) in a liver cancer background without clonal bias. The model facilitates dissection of A2M roles in protease inhibition, cytokine regulation, and acute phase responses.
SK-HEP-1 is a well-characterized human hepatic adenocarcinoma cell line derived from malignant ascites, commonly used to study hepatocellular carcinoma, metastasis, and angiogenesis. These cells exhibit robust proliferation and invasiveness, making them suited for exploring molecular drivers of liver cancer progression. The relevance of A2M in the tumor microenvironment, where it modulates proteolytic activity and growth factor availability, underpins the utility of this knockout model.
A2M encodes a broad-spectrum protease inhibitor that entraps enzymes via a bait region, forming complexes cleared by LRP1-mediated endocytosis. It also serves as a carrier for cytokines, notably TGF-beta, influencing its bioavailability and signaling. A2M expression is induced by IL-6, IL-1, TNF, and TGF-beta via STAT3 and NF-??B, and it inhibits proteases such as trypsin, thrombin, MMPs, and neutrophil elastase. Through interactions with LRP1, TGF-beta1, and other proteases, A2M integrates proteolytic cascades and cytokine networks. It modulates TGF-beta activity downstream of SMAD2/3.
Disrupting A2M in SK-HEP-1 cells likely alters protease-inhibitor balance, enhancing pericellular proteolysis and promoting invasion and metastasis. In the hepatic adenocarcinoma context, this model is valuable for liver fibrosis research, as A2M is an acute phase protein and TGF-beta regulator. Loss of A2M may increase MMP activity and TGF-beta signaling, driving extracellular matrix remodeling and migratory phenotypes. The polyclonal population captures tumor heterogeneity without clonal artifacts.
Applications include protease inhibition assays (trypsin, thrombin), TGF-beta bioavailability studies (ELISA, luciferase reporter), LRP1 binding/internalization assays, and cell invasion/migration experiments. The cells are also suitable for RNA-seq and proteomic profiling to assess global changes upon A2M loss. For more information, please contact Ascent Research.
